دورية أكاديمية
Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody.
| العنوان: | Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody. |
|---|---|
| المؤلفون: | Adachi E, Sedohara A, Arizono K, Takahashi K, Otani A, Kanno Y, Saito M, Koga M, Yotsuyanagi H |
| المصدر: | Emerging infectious diseases [Emerg Infect Dis] 2024 Aug; Vol. 30 (8), pp. 1668-1671. |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC) Country of Publication: United States NLM ID: 9508155 Publication Model: Print Cited Medium: Internet ISSN: 1080-6059 (Electronic) Linking ISSN: 10806040 NLM ISO Abbreviation: Emerg Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Atlanta, GA : National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), [1995- |
| مواضيع طبية MeSH: | HIV Infections*/drug therapy , HIV Infections*/virology , Hepatitis B virus*/genetics , Hepatitis B virus*/immunology , Virus Activation* , Hepatitis B*/virology , Hepatitis B*/drug therapy, Humans ; Male ; Pyridones/therapeutic use ; Hepatitis B Antibodies/blood ; Hepatitis B Antibodies/immunology ; Anti-HIV Agents/therapeutic use ; Pyrimidines/therapeutic use ; Middle Aged ; Hepatitis B Surface Antigens/immunology ; Hepatitis B Surface Antigens/blood ; Diketopiperazines |
| مستخلص: | A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine/tenofovir alafenamide to cabotegravir/rilpivirine. An immune escape mutation, E164V, was identified in the isolated HBV DNA. |
| References: | Int J Infect Dis. 2009 Jul;13(4):488-92. (PMID: 19081280) J Gastroenterol Hepatol. 2010 May;25(5):864-71. (PMID: 20546439) Viruses. 2019 Aug 24;11(9):. (PMID: 31450544) MMWR Recomm Rep. 2013 Dec 20;62(RR-10):1-19. (PMID: 24352112) Hum Vaccin Immunother. 2015;11(2):407-10. (PMID: 25692622) AIDS. 2021 Aug 1;35(10):1707-1708. (PMID: 34270493) Hepatol Commun. 2017 Nov 06;1(10):1014-1023. (PMID: 29404439) J Infect Dis. 2016 Jun 1;213(11):1735-42. (PMID: 26768256) J Clin Microbiol. 2007 Dec;45(12):3942-7. (PMID: 17942661) J Med Virol. 2012 Feb;84(2):198-206. (PMID: 22170538) J Acquir Immune Defic Syndr. 2023 Oct 1;94(2):160-164. (PMID: 37345994) Virol J. 2021 Nov 29;18(1):235. (PMID: 34844619) Cell Mol Gastroenterol Hepatol. 2021;12(5):1583-1598. (PMID: 34352407) Gastroenterology. 1997 Nov;113(5):1668-74. (PMID: 9352871) |
| فهرسة مساهمة: | Keywords: HBV; HBV reactivation; HIV; Japan; antiretroviral therapy; cabotegravir; hepatitis B; hepatitis B virus; rilpivirine; vaccine-escape mutation; viruses |
| المشرفين على المادة: | 0 (Pyridones) 0 (Hepatitis B Antibodies) 0 (Anti-HIV Agents) HMH0132Z1Q (cabotegravir) 0 (Pyrimidines) 0 (Hepatitis B Surface Antigens) 0 (Diketopiperazines) |
| تواريخ الأحداث: | Date Created: 20240723 Date Completed: 20240723 Latest Revision: 20240802 |
| رمز التحديث: | 20240802 |
| مُعرف محوري في PubMed: | PMC11286062 |
| DOI: | 10.3201/eid3008.240019 |
| PMID: | 39043430 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!